Posted by Michael Wonder on 11 Jun 2025
US FDA approves expanded indication for AbbVie's Mavyret (glecaprevir/pibrentasvir) as first and only treatment for people with acute hepatitis C virus
11 June 2025 - AbbVie today announced that the US FDA approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral therapy.
It is now approved for the treatment of adults and paediatric patients three years and older with acute or chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis.
